**תאריך: 10.8.2022**

**הצעה למינוי חדש/ קידום**

 **לחבר סגל באוניברסיטת בר-אילן**

1. **נתונים אישיים**:

|  |  |
| --- | --- |
| שם המועמד/ת בעברית: נימר עאסי | בלועזית: Nimer Assy |
| כתובת: פסוטה 251700 גליל מערבי | מקום לידה: פסוטה |
| מס' ת"ז: 57009193 | תאריך לידה: 01/09/1961 |
| מצב משפחתי: נשוי + 5 | תאריך עליה: אין |
| טלפון: 0507887915 | דואר אלקטרוני: nimera@gmc.gov.il |

1. **הדרגה המוצעת**: שנת הלימודים:
2. **השכלה**:

|  |  |  |  |
| --- | --- | --- | --- |
| השכלה: | שם האוניברסיטה או המוסד: | מחלקה: | שנת קבלת התואר או ההסמכה: |
| MD\DMD: | University of Louvain (UCL), Belgium |   | 1987 |
| נושא עבודת MD: Diabetic Nephropathy |
| התמחות ראשית:תת- התמחות: | מרכז רפואי רמב"ם | פנימית ב'  | 1994 |
| השתלמויות:Fellowship in HepatologyLiver transplant | University of Manitoba, CanadaUniversity of Western Ontario, Canada |  |    |
| תארים אקדמיים נוספים: | אין |  |  |
| פוסט דוקטורט  | אין |  |  |

1. **מינויים אקדמיים**:

|  |  |  |
| --- | --- | --- |
| דרגת מינוי: | שם האוניברסיטה: | שנת קבלת הדרגה: |
| פרופסור חבר  | בר אילן | 2011 |
| מרצה בכיר  | הטכניון | 2007 |

1. **תרומה להוראה ועשייה בפקולטה:**
* קלרקשיפ בפנימית א' נהריה: 24 שבועות (שני מחזורים), שנה רביעית
* קלרקשיפ בפנימית א' נהריה: 4 שבועות, שנה שישית
* רכז קורס ביואנרגטיקה, 2014-2011
* הרצאות בתחום הכבד, שנה רביעית; תלת וארבע שנתי, 2021-2011
* בוחן סטודנטים לקבלה לפקולטה לרפואה, אוניברסיטת בר אילן (מסר וצפת)
* בוחן לתואר שני בפקולטה לרפואה של אוניברסיטת בר אילן, על-ידי פרופ' אמנון הראל (גאנם מנאר)
* בוחן לתואר שלישי בפקולטה לרפואה של אוניברסיטת בר אילן, על-ידי ד''ר גל תנעמי מיטל (סיוון אליהו)
* בוחן לתואר שני בפקולטה לרפואה של אוניברסיטת בר אילן, על-ידי פרופ' דוד קרסיק ((MSC
1. **תפקיד מקצועי במוסד הרפואי**:

מנהל מחלקה פנימית א', המרכז הרפואי לגליל (נהריה), דרגה 9, 95% משרה, החל מ-1.2.2015

1. **מקומות עבודה קודמים**:
* מנהל שירות הכבד, מרכז רפואי זיו בצפת, 2014-2007, 95% משרה.
* מנהל מחלקה פנימית א', המרכז הרפואי לגליל, 2019-2015.
1. **הדרכת סטודנטים**:

|  |
| --- |
| שמות תלמידי MD הדרכה לעבודות גמר: |
| שם התלמיד:נטלי זילברשטייןמרווה חרפקג'ואינה עארףמעיין פרקיןנדאא נסארנאסר יוסףנאסר היבהעאסי מוסא  | שנת סיום:20132013201420152016201720182020 | מדריך שותף: | נושא העבודה: | פרסומים עם הסטודנט כמנחה (ציין מספר המאמר ברשימת הפרסומים): |
|  |  |  |  |  |
| הדרכת מתמחים למדעי יסוד: |
| שם המתמחה:ד"ר וליד קסיסד"ר עמאד אבו שקארהד"ר אחמד יאסיןד"ר סימון אבו שקארהד"ר אזואר נגארד"ר עלאא עמאשהד"ר קוליאדה אלכסנדרד"ר ג'ובראן ואלד"ר אבן סאלח עלאאד"ר עסלה חוסאםד"ר קפנינוב אינסה | שנת סיום:20202020201920192018201720152014201420142013 | מדריך שותף: | נושא העבודה: | פרסומים עם הסטודנט כמנחה (ציין מספר המאמר ברשימת הפרסומים): |
|  |  |  |  |  |
| שמות תלמידי תואר מוסמך MSc: |
| שם התלמיד:נסרין גנאים | שנת סיום:2019 | מדריך שותף:ד"ר מזיד פלאח | נושא העבודה:  | פרסומים עם הסטודנט כמנחה(ציין מספר המאמר ברשימת הפרסומים): |
|  |  |  |  |  |
| ‏ שמות תלמידי הדוקטור-PhD: |
| שם התלמיד:אתי אזולאי (לא סיימה את התואר בשל נסיבות רפואיות של בתה) | שנת סיום:2019  | מדריך שותף:ד"ר עידן כהן | נושא העבודה: | פרסומים עם הסטודנט כמנחה (ציין מספר המאמר ברשימת הפרסומים): |

1. **מלגות ופרסים**:

יש לציין את שמות המלגות/פרסים, הגוף המממן ואת שנות הזכייה

* פרס מרצה מעורר השראה, התאחדות הסטודנטים הארצית (2009)
* מרצה מצטיין ברצף, הפקולטה לרפואה של אוניברסיטת בר אילן (2020-2012)
1. **זכיה במענקי מחקר**

יש לציין את שמות הקרנות, שנות הזכייה, הסכום ושמות השותפים למחקר

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| תאריכי התחלה וסיום: | סוכנות/ מוסד המממן: | תחרותי או ממומן: | סטטוס (e.g, PI, Co-PI): | נושא: | סכום כולל: |
| 2018-2019 | Israel Cancer Association |   |  - In cooperation with Dr. Idan Cohen. | Characterization of recurrent mutation in H2B histone variants as potential novel oncohistone mutations controlling human jumping genes | 75,000 NIS |

1. **כנסים מדעיים**

1. Participation in organizing conferences
2. Plenary or invited talks
3. Contributed Talks, Posters and abstracts
4. Refereed papers in conference proceedings

a. National Conferences

|  |  |  |
| --- | --- | --- |
| **Name of Conference** | **Place and Date** | **Title of Lecture/Poster** |
| **Participation in organizing conferences** |
| Organizing committee, annual conferences of the Israeli Association for Study of the Liver (IASL)  |  , 2007-2011 |  |
| Nazareth meeting for the world hepatitis awareness day | Nazareth, 2009 |  |
| Biomedical research Conference of the Galilee  | Tal-Hai College; Kiryat Shmonah, Oct 25, 2011 | Chairman, member of the organizing committee |
| **Plenary Presentations** |
|  |  |  |
| **Invited non-Plenary**  |
| IASL Conferences |   | More than 30 oral presentations |
| Liver Meeting – Northern Committee | 2007-2011 | HBV, fatty liver, HCV |
| DOT 2009 | Hilton, Tel-Aviv, 2009 | Fatty liver disease |
| DOT 2010 | Tel Aviv, 2010 | Soft drink consumption (fructose) and fatty liver |
| IASL 2010 | Tel-Aviv, 2010 | Pharmacological therapy in NAFLD-atherosclerosis |
| Northern Committee for Diabetes, Obesity, and Hypertension  | Dan Carmel, Haifa, Sept 21, 2011  | Fatty liver as a cardiovascular risk factor |
| **Contributed Talks, Posters and Abstracts** |
| IASL 2000 | Eilat, 2000 | **Assy N**, Abassi Z, and Hussein O. Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis NASH. |
| IASL 2004 | Eilat, 2004 | **Assy N**, Lasri E, Grovsovski M, Svalb S, Hussein O. Antioxidative liver enzymes fail to contain oxidative stress in nonalcoholic fatty liver disease in rats on different dietary fatty acids. |
| IASL | Eilat, 2004 | **Assy N**, Shynin I, Mejirisky Y, Shen-Orr T, Mason T. Abnormal IGF-1 response to GH administration in patients with NAFLD. |
| IASL | Eilat, 2005 | **Assy N**, Schlesinger S, Hussein O. Elevated plasma protein C correlates with the presence of fatty liver (NASH and NAFLD). |
| IASL | Eilat, 2005 | **Assy N**, Bekirov I, Mejiritsky Y, Solomon L, Szvalb A. Association between thrombotic risk factors and extent of fibrosis in patients with nonalcoholic fatty liver disease. |
| Falk Symposium | Eilat, 2006 | **Assy N**, Grozovski M, Bersudsky I, Szvalb S and Hussein O. Effect of Insulin Sensitizing Agents, in combination with Ezetimibe, and Valsartan in rats with metabolic syndrome and fatty liver. |
| IASL | Tiberias, Mars 2007 | **Assy N**, Pruzansky Y, Hochberg Z, Gaitini D, Shen Orr Z, and Baruch Y. Blunted IGF-1 responsiveness to GH administration in decompensated cirrhosis: Correlation with MELD and Child score but not with portal hypertension and malnutrition. |
| IASL | Tiberias, Mars 2007 | Beniashvili Z, Hussein A, Dabush S, Hino B, and **Assy N**. HBV DNA levels at different clinical stages of chronic HBV (CHB). |
| The 12th Annual meeting of the Israeli Society for Research, Prevention and Treatment of Atherosclerosis in conjunction with the Frontiers in Cardiovascular Science | Eilat, 18-21 Oct, 2007  | Shatil T, Korem S, **Assy N**, Beniashvili Z, Grozovski M. The effect of antidiabetic agents on hepatic retinol binding protein 4 expression and lipid metabolism in rats with non-alcoholic fatty Liver undergoing partial hepatectomy. |
| The 12th Annual meeting of the Israeli Society for Research, Prevention and Treatment of Atherosclerosis in conjunction with the Frontiers in Cardiovascular Science | Eilat, 18-21 Oct, 2007  | Hussein O, Abu Gabai K, Grozovski M, Bersudsky I, **Assy N**, Karry R, Aviram M. The effect of insulin sensitizers (rosiglitazone and metformin), ezetimibe and valsartan (each alone or in combination) on plasma paraoxonase activity and mRNA expression in experimental rat non - alcoholic fatty liver disease. |
| the 3rd ORT Braude College Research Conference | Hagoshrim, 8-9 October, 2007 | Grozovski M, Shatil T, Korem S, Beniashvili Z, **Assy N**. Increased serum and hepatic RBP 4 level: an additional risk factor for experimental fatty liver disease. |
| 6th ICRS Annual meeting | Caesarea, 5-6 September, 2007 | Shatil T, Korem S, **Assy N**, Beniashvili Z, Grozovski M. “The effect o antidiabetic agents and partial hepatectomy on the retinol binding protein 4 level expression in rats with non-alcoholic fatty liver disease undergoing partial hepatectomy. |
| The Fourth ORT Braude College Interdisciplinary Research Conference | Nazareth Ilit, October, 2008 | Grozovski M, LipshizG, Korem S, **Assy N**: The effect of insulin sensitizing agents (ISA) on "Protein C" and on Paraoxonase mRNA expression in rats with fatty liver. |
| IASL 2008 | Eilat, 2008 | **Assy N**., Nasser G., Kamayse I., Nseir W and Grozovski M. "Soft drink consumption linked with fatty liver in patients without traditional risk factors. |
| The Annual Meeting of the Israeli SocietyforResearch, Prevention and Treatment of Liver Disease | Kfar Bloom, March 5-7, 2009 | Djibre A,MarmorA, Grosovski M, Farah R, Nassar F, and **Assy N**: Non Alcoholic Fatty Liver Diseases and Sub Clinical Coronary Atherosclerosis |
| IAGE. Gastroenterology Meeting | Tel Aviv, June 22, 2010 | **Assy N**. Nseir W., Rovman Y., Marmor A., Dvorin I., Daitzman M., Djibre A., Grosovski M. Liver Fat Accumulation Contributes more to the risk of Coronary Artery Disease than Visceral Fat. |
| Medical meeting for celebrating 100 years for Ziv Medical Center | Rosh Pina, October 8, 2010 | **Assy N**. Nseir W, Rovman Y, Marmor A, Dvorin I, Daitzman M, Djibre A, Grosovski M. Liver Fat Accumulation Contributes more to the risk of Coronary Artery Disease than Visceral Fat. |
| IASL | Eilat, 2011 | Nseir W, Marmor A, Abu Mouch S, Grosovski M, **Assy N**. Association between 25-OH Vitamin D Concentrations and risk of Coronary Artery Disease in patients with Nonalcoholic Fatty Liver Disease. |
| Biorefuah-2011 | Tel Hai, Kiryat Shemona, 2011 | Vintfield Y, Krichevsky L, Svzalb S, Grosovski M, and **Assy N**. Vitamin D and sitaglibtin/metformin treatment decrease hepatic triglyceride levels in SK-1 knock out mice with experimental Fatty Liver. |
| Biorefuah-2011 | Tel Hai, Kiryat Shemona, 2011 | Serum HDL and Vitamin D Levels are strongly associated with SVR in chronic hepatitis C naïve genotype-1 patients. |
| **Refereed papers in conference proceedings** |
|  |  |  |

b. International Conferences in Israel

|  |  |  |
| --- | --- | --- |
| **Name of Conference** | **Place and Date** | **Title of Lecture/Poster** |
| **Participation in organizing conferences** |
| First International liver meeting in The Galilee | Ramot, Tiberias May 13-14, 2010 | (Invited speakers from France and Canada attended) |
| European Association for Study of the Liver (EASL) Clinical School | Jerusalem, Israel May 15, 2011 | Chairman of a session on resection, ablation, and liver transplantation of hepatocellular carcinoma. |
| **Plenary Presentations** |
|  |  |  |
| **Invited non-Plenary**  |
|  |  |  |
| **Contributed Talks, Posters and Abstracts** |
|  |  |  |
| **Refereed papers in conference proceedings** |
|  |  |  |

c. International Conferences Abroad

|  |  |  |
| --- | --- | --- |
| **Name of Conference** | **Place and Date** | **Title of Lecture/Poster** |
| **Participation in organizing conferences** |
|  |  |  |
| **Plenary Presentations** |
|  |  |  |
| **Invited non-Plenary**  |
| Belt & Road International Conference on Hepatobiliary Carcinoma and Infectious Diseases (BRICHID) | University of Peking, China, July 2019 | IGF-1 as a liver reserve assessment tool in Hepatocellular Carcinoma. |
| EPS Global 1ST International Conference of microbes (WCM1-2011) | Beijing China, July 30 - Aug 1, 2011 | Vitamin D and chronic liver disease |
| First world congress of viruses and infections (WCV1-2010) | Busan, Korea, July 31 -august 3, 2010 | Hepatitis C and the Metabolic Syndrome: Chairman of session (3 hours) on hepatitis B |
| EASL: European association for the study of the Liver | Vienna, Austria, April 2010 | Main lecture: oral presentation: Vitamin D supplements improve SVR in chronic hepatitis C in naïve patients treated with Peg interferon alpha and ribavirin |
| EHRLICH II - 2nd World Conference on Magic Bullets - Celebrating the 100th Anniversary of the Nobel Prize Award to Paul Erlich | Nürnberg, Germany, October 3-5, 2008 | The changes in renal function after a single dose of intravenous Furosemide in patients with compensated liver cirrhosis |
| EASL - European association for the study of the Liver | Berlin 2004 | Satellite Symposium: Prospects for Improved Liver Disease Management in Chronic Hepatitis B; personal Approach of patients with HBV: "A day in the life of Dr Assy N." |
| **Contributed Talks, Posters and Abstracts** |
| Hepatology (AASLD) 1994 | 1994 |  **Assy N**, Hochberg Z, Amit T, Enat R and Baruch Y. Growth hormone stimulated insulin like growth factor 1 (IGF-1) and binding protein-3 in liver cirrhosis. |
| EASL 1996 | 1996 | Baruch Y, **Assy N**, Amit T, and Hochberg Z. Spontaneous pharmacokinetics of growth hormone in liver cirrhotic patients. |
| Canadian Digestive Diseases Week | Banff, Canada, 1996 | **Assy N**, Rosser BG, Graham GR and Minuk GY. Risk of sedation for upper Gastrointestinal endoscopy exacerbating sub clinical hepatic encephalopathy in patients with cirrhosis. |
| Hepatology (AASLD) 1996 | 1996 | **Assy N**, KDE Kaita, D Mymin, C Levi, and GY Minuk. Fatty infiltration of the liver in hyperlipidemic patients. |
| Hepatology (AASLD) 1996 | 1996 | **Assy N**, NM Pettigrew, SS Lee, RK Chaudhary, J Johnson, and GY Minuk. Are chronic hepatitis C viral Infections more benign in patients with hemophilia? |
| Hepatology (AASLD) 1996 | 1996 | Gong WY, **Assy N**, M Zhang, and Minuk GY. Arrested hepatocyte proliferation following partial hepatectomy in rats. |
| Canadian Digestive Diseases Week | Quebec, Canada, 1997 | **Assy N**, and Adams PC. Predictive value of family history in the diagnosis of hereditary hemochromatosis. |
| Hepatology (AASLD) 1997 | 1997 | Baruch Y, **Assy N**, Krasik A, and Shoshany G. The effect of vascular endothelial growth factor (VEGF) on liver growth. |
| Hepatology (AASLD) 1997 | 1997 | **Assy N**, Hochberg Z, Enat R, and Baruch Y. Prognostic value of GH-stimulated insulin-like growth factor -1 (IGF-1) and its binding (IGBP-3) generation in patients with compensated and decompensated liver cirrhosis. |
| Hepatology (AASLD) 1997 | 1997 | **Assy N**, YW Gong, M Zhang, NM Pettigrew, D Pashniak and GY Minuk. The use of proliferating cell nuclear antigen (PCNA) m RNA and protein levels as a marker of liver regeneration following partial hepatectomy in rats. |
| Transplantation 1997 | 1997 | **Assy N**, Minuk GY, Myers P, Simon V, and Ghent CN. Immunosuppression withdrawal in stable liver transplant recipients. |
| Hepatology (AASLD) 1998 | 1998 | **Assy N**, Hoffman R, Brenner B, and Baruch Y. Budd-Chiari syndrome associated with factor V Leiden mutation. |
| IASLD 1998  | 1998 | **Assy N**, Hoffman R, Lanir N, Brenner B, Baruch Y. Budd-Chiari syndrome associated with factor V Leiden mutation: A report of 6 patients. |
| AASLD 1998  | 1998 | **Assy N**, Spira G, Paizi M, Shankar L, Kraizer Y, Cohen T, Neufeld G, Dabbah B, and Baruch Y. Effect of vascular endothelial growth factor on hepatic regenerative activity following partial hepatectomy in rats. Hepatology. |
| Hepatology 1998 (AASLD) | 1998 | **Assy N**, Pruzansky Y, Gaitini D, Hochberg Z, Enat R, and Baruch Y. Changes in insulin-like growth factor-1 release after growth hormone administration in patients with different grades of liver cirrhosis. |
| Hepatology ‏1998 (AASLD) | 1998 | Zhang M, Gong Y, **Assy N**, and Minuk GY. Inhibition of alpha-fetoprotein gene expression and cell proliferation by muscimol, a gamma aminobutric acid receptor agonist, in a human hepatocellular carcinoma. |
| Hepatology 1999 (AASLD) | 1999 | Spira G, Kraizer Y, Paizi M, and **Assy N**. Vascular endothelial growth factor and respective monoclonal antibodies can modulate liver cell proliferation following partial hepatectomy in rats. |
| Hepatology 2001A (AASLD) | Boston, USA, 2001 | **Assy N**, Gorenberg M, Awawdeh M, and Lerman A. Clinical Implication of DMSA uptake by the kidneys in cirrhotic patients with clinically normal renal function. |
| EASL 2004 | Berlin, Germany, 2004 | **Assy N**, Kayal M, Mejirisky Y, Gorenberg M, Husseion O, and Schlesinger S. The Changes in renal function after a single dose of intravenous furosemide in patients with compensated liver cirrhosis. |
| 15th International Symposium on Drugs Affecting Lipid Metabolism | Venice, Italy, October 24-27, 2004  | Hussein O, Grozovski M, Lasri E, Slab S, **Assy N.** Monounsaturated fats decrease hepatic lipid content in nonalcoholic fatty liver diseases in rats. |
| Falk Symposium | Berlin 2005 | **Assy N**, Grozovski M, Bersudsky I, Szvalb S and Hussein O. Effect of Insulin Sensitizing Agents, in combination with Ezetimibe, and Valsartan in rats with metabolic syndrome and fatty liver. |
| EASL 2006 | Vienna, Austria, 2006 | **Assy N**, Davidov V, Grozovski M, and Mijiriski Y. Protein C Activity Predicts NAFLD independently of classic risk factors, metabolic syndrome, and C-reactive protein. |
| Falk Symposium | Dresden, Germany, Oct 2007 | **Assy N**, Pruzansky Y, Gaitini D, Shen Orr Z, Hochberg Z, Minuk GY, and Baruch Y. Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepatocellular dysfunction. |
| The 58th Annual Meeting of the American Association for the Study of the Liver Diseases | Boston, USA, November 2007 | Beniashvilli Z, Grozovski M, Daboush S, Erdstein P and **Assy N**. “The use of new normal ALT values differentiates better HBeAg (-) chronic hepatitis B from inactive carrier state.  |
| The 16th International Symposium on Drugs Affecting Lipid Metabolism | New York, USA, 4-7 October 2007 | Hussein O, Abu Gabai K, Grozovski M, Bersudsky I, **Assy N**, karry R, Aviram. The effect of insulin sensitizers (rosiglitazone and metformin), ezetimibe and valsartan (each alone or in combination) on plasma paraoxanase activity and mRNA expression in experimental rat non - alcoholic fatty liver disease. |
| EASL 2008 | Milan, Italy, 2008 | **Assy N**, Nasser G, Grosovski M, Nseir W, Beniashvili Z, and Kamayse I. Soft drink consumption linked with fatty liver (NASH and NAFLD) in patients with no obvious traditional risk factors. |
| EASL 2008 | Milan, Italy, 2008 | Grozovski M, Shatil T, Beniashvili Z, Korem S, and **Assy N**. Retinol binding protein-4 expression is up regulated in rats with fatty liver during quiescent and regenerative state and improves with insulin sensitizing agents. |
| 15th International Symposium on Hepatitis C Virus & Related Viruses | San Antonio, USA, October, 2008 | **Assy N**, Dabush S, Ali T, Grozovski M and Nassar F: Serum cholesterol levels at week 4 as predictors of sustained viral response in patients with chronic hepatitis C infection. |
| The 3rd International Falk Symposium | Mainz, Germany, September 2008 | **Assy N**, Shatil T and Grozovski M: The effect of insulin sensitizing agents (ISA) on "Protein C" and on Paraoxonase mRNA expression in rats with fatty liver.  |
| International Liver Congress (ICL) | Hong Kong, China, 12-15 June, 2008 | Grozovski M, Shatil T, Beniashvili Z, Korem S and **Assy N.** "Retinol binding protein 4 expression is up regulated in rats with fatty liver during quiescent and regenerative state and improves with insulin sensitizing agents. |
| EASL 2009 | Copenhagen, Denmark, 2009 | Abid A, Taha O, Nseir W, Farah R, Grosovski M, **Assy N**. [Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome](http://www.ncbi.nlm.nih.gov/pubmed/19765850). |
| 44th Annual Meeting of the European Association for the Study of the Liver | Copenhagen, Denmark, April 26, 2009 | Extended Treatment Duration in Chronic hepatitis C Genotype 1 Infected slow -Responders: Final Results of the SUCCESS Study. M. Buti, Y. Lurie, N.G. Zakharova, N.P. Blokhina, A. Horban, C. Sarrazin, L. Balciuniene, R. Chen, X. Yu, R. Faruqi, R. Esteban. |
| The 5th International Seoul Liver Symposium Liver | Seoul, Korea, September 10-12, 2009 | Grozovski M, DjibreA, Daod D, Marmor M, **Assy N**: Association between excessive soft drink consumption and coronary artery disease and early atherosclerosis. |
| 3rd International Congress on Prediabetes and the Metabolic Syndrome | Nice, France, April 2009 | Grozovski M, Djibre A, Farah R, Nassar F, Marmor A, **Assy N**: Non Alcoholic Fatty Liver Diseases and Sub Clinical Coronary Atherosclerosis. |
| The 19th Conference of the APASL | Hong Kong SAR, China, Feb 2009 | Grozovski M, Lipez G and **Assy N**:Effect of insulin sensitizing agents (ISA) on hepatic “protein C” and paraoxonase m-RNA expression in rats with fatty liver. |
| AASLD 2009 | Boston, USA, 2009 | Kamaysi I, Nseir W, Alexandrov O, Isakson A, 4 Mysh V, 4 Dabbah K, and **Assy N**. Subclinical hepatic encephalopathy in cirrhotic patients is not aggravated by sedation with propofol compared to midazolam (Abstract) |
| AASLD 2009 | Boston, USA, 2009 | Abu Mouch S,Fireman Z, Jarchovs.ky J, and **Assy N.** Vitamin D supplement improve SVR in chronic hepatitis C (genotype 1) in naïve patients treated with peginterferon alpha and ribavirin. (late breaking Abstract) |
| AASLD 2009 | Boston, USA, 2009 | Nassar F, Nseir William; Alon MarmorRovman Y, Dvorin I, Djibre A, Grosovski MDaitzman M, **Assy N**. Liver Fat Accumulation Contributes more to the risk of Coronary Artery Disease than Visceral Fat accumulation (Abstract) |
|  |  | E.J. Gane, H.L. Chan, G. Choudhuri, D.J. Suh, A. Chutaputti, R. Safadi, T. Tanwandee, S. Thongsawat, **N. Assy,** S.K. Sarin, W. Bao, A. Trylesinski, C. Avila. Treatment of decompensated HBV-Cirrhosis: results from two years randomized trial with Telbivudine or Lamivudine (talk) |
|  |  | Abu Mouch, Z. Fireman, J. Jarchovsky, **N. Assy**: Vitamin D supplement improve SVR in chronic hepatitis C (genotype 1) naïve patients treated with interferone and ribavirin (talk) |
| EASL | Vienna, Austria, 2010 | W.A. Long, D. Takov, K. Tchernev, I. Kotzev, A. Rigney, Z. Krastev, S. Stoynov, R. Balabanska, E. Lawitz, Z. Younossi, R. Ghalib, E. Zuckerman, R. Safadi, R. Tur-Kaspa, N. **Assy,** Y. Lurie. [Q2 week controlled release interferon alpha -2b +ribavirin reduces flu-like symptoms >50% and provides equivalent efficacy in comparison to weekly pegylated interferon alpha 2b +ribavirin in treatment naïve genotype 1 chronic hepatitis C: results from empower. A randomized open label 12-week comparison in 133 patients](http://www.kenes.com/easl2010/Posters/Abstract10.htm) (talk) |
| AASLD | Boston, USA 2010  | N. William, M. Grosovski, **N. Assy**. Fatty liver disease predicts recurrent bacterial infections independently by metabolic syndrome. |
| EASL | Vienna, Austria 2010 | A. Ibrahim, S. Abo Mouch, A. Marmor, A. Djibre, **N. Assy**. Retinal vessel diameter, carotid artery IMT and the incidence of coronary artery disease in patients with NAFLD. |
| EASL | Vienna, Austria 2010 | F. Nassar, A. Djibre, A. Marmor, **N. Assy**. Association between excessive soft drink consumption, nonalcoholic fatty liver disease (NAFLD), and coronary artery diseases. |
| EASL | Vienna, Austria 2010 | Nseir W, Marmor A, Abu Mouch S, Grosovski M, **Assy N**. Association between 25-OH Vitamin D Concentrations and risk of Coronary Artery Disease in Patients with Nonalcoholic Fatty Liver Disease. |
| EASL | Vienna, Austria 2010 | Abu Mouch S and **Assy N**. Vitamin D supplementation improves viral response in chronic hepatitis C patients with genotype 2/3 and high viral load treated with peg interferon alpha-and ribavirin. |
| AASLD | Boston, USA 2010  | W.A. Long, E. Lawitz, Y. Lurie, Z. Krastev, D. Takov, K.G. Tchernev, A. Rigney, **N. Assy**, Z.M. Younossi. Adverse Event Reporting During HCV Treatment Via Weekly Clinic Visits Substantially Underestimates Flu Frequency & Severity Compared to Daily ePRO: Results From 133 Patients In EMPOWER study (Late Breaking abstract) |
| The 21st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2011) | QSNCC, Bangkok, Thailand, 17-20 February 2011 | Nseir W, Marmor A, Abu Mouch S, Grosovski M, **Assy N**. Association between 25-OH Vitamin D Concentrations and risk of Coronary Artery Disease in patients with Nonalcoholic Fatty Liver Disease. |
| EASL 2011 | Berlin, Germany, 2011 | Nseir W, Hussein T, Khateeb J, Grosovski M, and **Assy N**. Nonalcoholic Fatty Liver Disease is Strongly Associated with Recurrent Bacterial. Infections Independently by Metabolic Syndrome. |
| EASL 2011 | Berlin, Germany, 2011 | Nseir W,Morad G, Abu Mouch S,Djibre A, Nassar F, and **Assy N**.Serum HDL and Vitamin D Levels are strongly Associated with SVR in Chronic Hepatitis C Naïve Genotype-1 patients. |
| EASL 2011 | Berlin, Germany, 2011 | **Assy N**, Djibre A, Dabush S, Ali T, and Abu Mouch S. Vitamin D Supplements Prevent Myalgia and Elevation of CPK in Chronic Hepatitis B Patients Treated with Telbivudine. |
| BIT 1st Annual world congress of microbes - 2011 (WCM-2011) | 2011 | **Assy N**. Vitamin D in chronic liver disease: (Special emphasis on chronic hepatitis c viral infection (talk) |
| EASL 2020 | London, England, 2020 | Yasin A, **Assy N**, and Sbeit Wisam. Neutrophil to Lymphocytes ratio (NLR), procedure related risk factors (stent and stone crushing) Predicts post-ERCP Pancreatitis (poster).  |
| EASL 2020 | London, England, 2020 | Abu Shqara S., Saad E, Barhoum M and **Assy N.** High SOFA Score and Low serum albumin predicts early mortality in patients with ischemic hepatitis**.** Department of Medicine A, Galilee Medical Center, Bar Ilan University, The Azrieli Faculty of Medicine, Israel. |
| **Refereed papers in conference proceedings** |
| EASL, AASLD, IASL |  | **Assy N**, Hochberg Z, Amit T, Enat R and Baruch Y. Growth hormone stimulated Insulin like growth factor 1 (IGF-1) and binding protein -3 in liver cirrhosis. J Hepatol 1997; 27: 796-802 |
| AASLD Post graduate course 2018 |  | [Predictive value of family history in diagnosis of hereditary hemochromatosis.](https://www.ncbi.nlm.nih.gov/pubmed/9201100) **Assy N**, Adams PC. Dig Dis Sci. 1997 Jun;42(6):1312-5. |
| AASLD |  | **Assy N**, Gong YW, Zhang M, Pashniak D and Minuk GY. The use of proliferating Cell nuclear antigen as a marker of liver regeneration following partial Hepatectomy in rats. J Lab Clin Med 1998; 131:251-256. |
| AASLD |  | **Assy N**, Rosser BG, Graham GR and Minuk GY. Risk of sedation for upper gastrointestinal endoscopy exacerbating sub clinical hepatic encephalopathy in patients with cirrhosis. Gastrointestinal Endoscopy 1999; 49:690-694. |
| AASLD |  | **Assy N**, Kaita KDE, Mymin D, Levi C and Minuk GY. Fatty infiltration of the liver in Hyperlipidemic patients. Dig Dis SCI 2000; 45:1929-1934. |
| AASLD |  | [**Assy N**, Adams PC, Myers P, Simon V, Minuk GY, Wall W, Ghent CN.](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17589339&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum) Randomized Controlled Trial of Total Immunosuppression Withdrawal in Liver Transplant Recipients: Role of Ursodeoxycholic Acid. Transplantation. 2007; 83:1571-1576. |
| EASL |  | Abid A, Taha O, Nseir W, Farah R, Grosovski M, **Assy N**. [Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome.](http://www.ncbi.nlm.nih.gov/pubmed/19765850) J Hepatol. 2009 ;51:918-24 |
| EASL, AASLD |  | **Assy N**, Djibre A, Farah R, Grosovski M, Marmor A. [Presence of coronary plaques in patients with nonalcoholic fatty liver disease.](http://www.ncbi.nlm.nih.gov/pubmed/20093511) Radiology. 2010;254:393-400. |
| EASL, AASLD LB |  | Abu Mouch S, Fireman Z, Jarchovs.ky J, and **Assy N**. Vitamin D supplement improve SVR in chronic hepatitis C (genotype 1) in naïve patients treated with peginterferon alpha and ribavirin. WJG 2011 In press |

d.

|  |  |  |
| --- | --- | --- |
| **Invited Professorships Institution** | **Grand Rounds Date** | **Title:** |
|  |  |  |
|  |  |  |

1. **נסיון מקצועי אחר**:
* חבר ועדת משרד הבריאות בענייני כבד (יו"ר זמיר הלפרין), תל אביב, 2015-2011
* מנהל מרפאה פנימית, קופ"ח מכבי, פסוטה
* יועץ על במחלות כבד בכללית מושלם ובמכבי
* חבר ועדת תמותה של משרד הבריאות בעניין אריאלה להט ז"ל (ד''ר בעז לב, נציב קבילות הציבור, עם פרופ' דורון קופלמן)
* חבר הוועדה לקידום רופאים Fellowship - המרכז הרפואי לגליל (עם פרופ' סוסטיאל וד''ר זיו פז)
* יו"ר ועדת הבריאות של הסטודנטים לרפואה בפקולטה לרפואה של אוניברסיטת בר אילן בצפת
* יו"ר ועדת הכרה בהתמחות מועצה מדעית, פרופ' יורם שפירא (ד''ר חכים פהד הרדמה בי"ח אנגלי נצרת)
* יועץ סל הבריאות בתחום הכבד, 2015-2012
* חבר במועצה הלאומית למחלות כבד ותזונה, משנת 2014
* חבר בוועדה למיפוי עתודה רפואית,GMC
* בוחן בבחינות שלב א' ושלב ב'
1. **תחומי התמחות מדעיים**:
* מעבדה מטבולית לחקר הכבד במרכז רפואי לגליל
* כבד שומני ותסמונת מטבולית (עבודה של ד''ר בשיר על הקשר בין מיקרוביום לכבד שומני)
* ביטוי IL-1 בכבד שומני לאחרPHX
* מנבאים של דלקת כבד איסכמי (Ischemic Hepatitis)
* IGF-1 Generation Test
* The Role of Eotaxins in the Pathogenesis and Treatment of Autoimmune Pancreatitis
1. **מידע נוסף**:
* חבר החברה הישראלית לחקר הכבד (IASL),
* חבר החברה האירופאית לחקר הכבד (EASL)
* חבר החברה האמריקאית לחקר הכבד, (AASLD)
* זכייה בתוכנית מצפן (כוכבי הצפון) בפקולטה לרפואה של אוניברסיטת בר אילן בצפת לשנת 2020 (שני רופאים).
1. **רשימת פרסומים:**

Contribution to study

**A**- Initiator of the study; **B**- Performing the study

**C**-Writing the manuscript draft; **D**-Reviewing the draft

**Date of last promotion:**

1. **Hypothesis-driven clinical or basic research**

Until last promotion

1. **Assy N**, and Adams PC. Predictive value of family history in the diagnosis of hereditary Hemochromatosis. *Dig Dis Sci* 1997; 42:1312-1315.

IF:2.06, Rank: 40/71 (Gastro&hepatol). Contribution: A,B,C,D

2. **Assy N**, Hochberg Z, Amit T, Enat R and Baruch Y. Growth hormone stimulated Insulin like growth factor 1 (IGF-1) and binding protein -3 in liver cirrhosis. *J Hepatol* 1997; 27: 796-802.

IF: 9.33, Rank: 4/71 (Gastro&hepatol). Contribution: A,B,C,D

3. Minuk GY, **Assy N**, Ding LX, Gauthier T, and Pashniak D. Effect of quinolone antibiotics on hepatic growth and protein synthesis following partial hepatectomy in rats. *J Gastroenterol Hepatol* 1997; 12: 54-57. Comment in: J Gastroenterol Hepatol 1997; 12: 44-6.

IF:2.4, Rank: 33/71 (Gastro&hepatol). Contribution: B,D

4. Baruch Y, **Assy N**, Kramsky R, and Enat R. Safety of conversion from cyclosporine sand immune to cyclosporine neoral in stable liver transplant patients*. Transplant Proc* 1998; 30:1852-1853.

IF:0.99, SJR 0,124 (transplant). Contribution: A,B,C,D

5. **Assy N**, Hochberg Z, Enat R, and Baruch Y. Prognostic value of GH-stimulated insulin- Like growth factor -1 (IGF-1) and its binding (IGBP-3) generation in patients with compensated and decompensated liver cirrhosis. *Dig Dis Sci* 1998; 43:1317-1321.

IF: 2.06, Rank: 40/71 (Gastro&hepatol). Contribution: A,B,C,D

6 Baruch Y, **Assy N**, Amit T, and Hochberg Z. Spontaneous pharmacokinetics of growth hormone in liver cirrhotic patients. *J Hepatol* 1998; 28:414-419.

IF:9.33, Rank: 4/71 (Gastro&hepatol). Contribution: A,B,C,D

7. Kaita KDE, **Assy N**, Gauthier T, and Minuk GY. The beneficial effects of Ciprofloxacin on survival and hepatic regenerative activity in an animal model of Fulminant hepatic failure. *Hepatology* 1998; 27:533-536.

IF: 10.88, Rank: 2/71 (Gastro&hepatol). Contribution: A,C,D

8. **Assy N**, Gong YW, Zhang M, Pashniak D and Minuk GY. The use of proliferating Cell nuclear antigen as a marker of liver regeneration following partial Hepatectomy in rats. *J Lab Clin Med* 1998; 131:251-256.

IF: 2.19, Rank: 5/18 (medical laboratory technology category). Contribution: A,B,C,D

9. Baruch Y, **Assy N**, Reisner S, Blendis LM, Berry E, Enat R, and Bomzon A. A pilot study on the hemodynamic effect of short term ursodeoxycholic acid therapy in patients with stable liver cirrhosis. *Am J Gastroenterology*. 1999; 94:3000-3004.

IF: 6.88, Rank: 5/71 (Gastro&hepatol). Contribution: A,B,C,D

10**. Assy N**, Rosser BG, Graham GR and Minuk GY. Risk of sedation for upper gastrointestinal endoscopy exacerbating sub clinical hepatic encephalopathy in patients with cirrhosis. *Gastrointestinal Endoscopy* 1999; 49:690-694.

IF: 5.6, Rank: 7/71 (Gastro&hepatol). Contribution: A,B,C,D

11. **Assy N**, Paizi M, Gaitini D, Baruch Y, and Spira G. Clinical implication of serum VEGF levels in cirrhotic patients with or without portal hypertension. *World J Gastroenterology* 1999; 5: 296-300.

IF: 2.24, Rank: 35/71 (Gastro&hepatol). Contribution: A,B,C,D

12. **Assy N**, Gong YW, Zhang M and Minuk GY. Appearance of an inhibitory cell nuclear antigen in rat and human serum during variable degrees of hepatic regenerative activity. *World J Gastroenterol (WJG)* 1999; 5:103-107.

IF: 2.24, Rank: 35/71 (Gastro&hepatol). Contribution: A,B,C,D

13. **Assy N**, Spira G, Paizi M, Shankar L, Kraizer Y, Cohen T, Neufeld G, Dabbah B, and Baruch Y. Effect of vascular endothelial growth factor on hepatic regenerative activity following partial hepatectomy in rats. *J Hepatol* 1999; 30:911-915.

IF: 9.33, Rank: 4/71 (Gastro&hepatol). BY. Research Student. Contribution: A,B,C,D

14. **Assy N**, Kaita KDE, Mymin D, Levi C and Minuk GY. Fatty infiltration of the liver in Hyperlipidemic patients. *Dig Dis SCI* 2000; 45:1929-1934.

IF:2.06, Rank: 40/71 (Gastro&hepatol). Contribution: A,B,C,D

15. **Assy N**, and Minuk GY. Serum aspartate aminotransferase (AST) values as a useful predictor of histologic features of chronic HCV infection in adults. *Am J Gastroenterology* 2000; 95:1545-1551.

IF: 6.88, Rank: 5/71 (Gastro&hepatol). Contribution: A,B,C,D

16. M Zhang, Gong W, **Assy N,** and GY Minuk. Regulation of alpha fetoprotein and albumin gene expression by gamma-aminobutric acid receptor agonists in a human hepatocellular carcinoma cell line. *J Hepatol* 2000; 32:85-91

IF: 9.33, Rank: 4/71 (Gastro&hepatol). BY. Research Student. Contribution: A,B,C,D

17. Edoute Y, Hussein O, Malberger E, Yerushalmi R, Tibon-Fisher O, **Assy N.** Diagnostic accuracy of direct fine-needle aspiration of levier lesions: a prospective study of 107 patients in peripheral community center with limited technological capability. *Arch gastroenterohepatology* 2001; 20:19-24. (Editorial 20:14-18).

IF:1.67, Rank: 98/114, SJR 0.025 (Gastro&hepatol). Contribution: A,B,C,D

18. Kraizer Y, Mawasi N, Seagal J, Paizi M, **Assy N**, Spira G. Vascular endothelial growth factor and angiopoietin in liver regeneration. *Biochem Biophys Res Com* 2001; 87:209-215.

IF:2.59, Rank: 25/121, SJR 0,398 (Biophysics). KY. Research Student. Contribution: A,B,C,D

19. Hussein O, Szvalb S, Van den Akker-Berman LM, and **Assy N**. Liver regeneration is not altered in patients with nonalcoholic steatohepatitis (NASH) when compared to chronic hepatitis C infection with similar grade of inflammation. *Dig Dis Sci*. 2002; 47:1926-31.

IF:2.06, Rank: 40/71(Gastro&hepatol). VL, research student, Contribution: A,B,C,D

20. **Assy N**, Bekirov I, Mejiritsky Y, Solomon L, Szvalb S, and Hussein O. Association between thrombotic risk factors and extent of fibrosis in patients with nonalcoholic Fatty liver disease. *World J gastroenterology* 2005; 11(37):5834-9.

IF: 2.24, Rank: 35/71 (Gastro&hepatol). BI, Research student. Contribution: A,B,C,D

21. **Assy N**, Kayal M, Mejirisky Y, Gorenberg I, Hussein O, and Sorina Schlesinger. The Changes in Functional Renal Mass after a Single Dose of Intravenous Furosemide in Patients with Compensated Liver cirrhosis. *BMC Gastroenterol*. 2006; 6:39-46.

IF:2.46, Rank: 32/71 (Gastro&Hepatol). A.M. Research Student. Contribution: A,B,C,D

22. [**Assy N**, Grozovski M, Bersudsky I. Szvalb S, Hussein O.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16865780&query_hl=1&itool=pubmed_docsum) Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. *World J Gastroenterol*. 2006; 12:4369-76.

IF: 2.24, Rank: 35/71 (Gastro&hepatol). Contribution: A,B,C,D

23. Hussein O, Schlesinger S, Szvalb S, and **Assy N.** Orlistat reverse fatty infiltration and improve hepatic fibrosis in obese patients with nonalcoholic steatohepatitis NASH). *Dig Dis Sci* 2007; 52:2512-9.

IF:2.06, Rank: 40/71 (Gastro&hepatol ). Contribution: A,B,C,D

24.[Hussein O, Gefen Y, Zidan JM, Karochero EY, Luder AS, **Assy N**, Sror ES, Aviram MY.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17070510&query_hl=1&itool=pubmed_docsum) LDL oxidation is associated with increased blood hemoglobin A1c levels in diabetic patients. *Clin Chim Acta*. 2007; 377:114-8.

 IF: 2.53, SJR 0.23 ([Biomedical Sciences](http://www.google.com/url?q=http://biomedicalsciencesblog.blogspot.com/2010/06/2009-journal-impact-factors.html&sa=U&ei=PYhDTtK3BoTJswaf88mjAg&ved=0CBMQFjAB&sig2=kpWOBmK-hf2LSR2k4Af1Ng&usg=AFQjCNHnwQwS57W-KPEULIOzcN0opfj5JQ)). Contribution: D

25.[**Assy N**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Assy%20N%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Pettigrew N](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Pettigrew%20N%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Lee SS](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Lee%20SS%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Chaudhary RK](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Chaudhary%20RK%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Johnston J](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Johnston%20J%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Minuk GY](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Minuk%20GY%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus). Are Chronic Hepatitis C Viral Infections More Benign in Patients with Hemophilia? *Am J Gastroenterol*. 2007;102:1672-6

IF: 6.88, Rank: 5/71 (Gastro&hepatol). Contribution: A,B,C,D

26. [**Assy N**, Adams PC, Myers P, Simon V, Minuk GY, Wall W, Ghent CN.](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17589339&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum) Randomized Controlled Trial of Total Immunosuppression Withdrawal in Liver Transplant Recipients: Role of Ursodeoxycholic Acid. *Transplantation*. 2007; 83:1571-1576.

IF:3.67, Rank: 11/40 (Surg). Contribution: A,B,C,D

27**.** [**Assy N**, Hussein O, Khalil A, Luder A, Szvalb S, Paizi M, Spira G.](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17372820&ordinalpos=7&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum) The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis. *Dig Dis Sci*. 2007; 52:1187-93

IF:2.06, Rank: 40/71 (Gastro&Hepatol). A.K. Research Student. Contribution: A,B,C,D

28. [Hussein O, Grosovski M, Lasri E, Svalb S, Ravid U, **Assy N**.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17230603&query_hl=1&itool=pubmed_docsum) Monounsaturated fat decreases hepatic lipid content in non-alcoholic fatty liver disease in rats. *World J Gastroenterol*. 2007; 13:361-368

IF: 2.24, Rank: 35/71 (Gastro&hepatol). Contribution: A,B,C,D

29. **Assy N**, Nasser G, Kamayse I, Nseir W, Beniashvili Z, Djibre A, Grosovski M. [Soft drink consumption linked with fatty liver in the absence of traditional risk factors.](http://www.ncbi.nlm.nih.gov/pubmed/18925303) *Can J Gastroenterol*. 2008;22:811-6.

IF:1.55, Rank: 49/71 (Gastro&hepatol). Contribution: A,B,C,D

30. **Assy N**, Pruzansky Y, Gaitini D, Shen Orr Z, Hochberg Z, Baruch Y. [Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepato cellular dysfunction.](http://www.ncbi.nlm.nih.gov/pubmed/18456366) *J Hepatol*. 2008; 49:34-42

IF:9.33, Rank: 4/71 (Gastro&hepatol). BY. Research Student. Contribution: A,B,C,D

31. **Assy N**, Beniashvili Z, Djibre A, Nasser G, Grosovski M, Nseir W. [Lower baseline ALT cut-off values and HBV DNA levels better differentiate HBeAg- chronic hepatitis B patients from inactive chronic carriers.](http://www.ncbi.nlm.nih.gov/pubmed/19554656) *World J Gastroenterol*. 2009;15:3025-31

IF: 2.24, Rank: 35/71 (Gastro&hepatol). Contribution: A,B,C,D

32. Aid A, Taha O, Nseir W, Farah R, Grosovski M, **Assy N**. [Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome.](http://www.ncbi.nlm.nih.gov/pubmed/19765850) *J Hepatol*. 2009;51:918-24

IF:9.33, Rank: 4/71 (Gastro&hepatol). A.A. Research Student. Contribution: A,B,C,D

33. **Assy N**, Djibre A, Farah R, Grosovski M, Marmor A. [Presence of coronary plaques in patients with nonalcoholic fatty liver disease.](http://www.ncbi.nlm.nih.gov/pubmed/20093511) *Radiology*. 2010;254:393-400

IF:6.06, Rank: 2/40 (Radiology). D.A. Research Student. Contribution: A,B,C,D

34. Nseir W, Khateeb J, Tatour I, Haiek I, and **Assy N**. Long Term Statin Therapy May Reduce the Severity of Chronic Gastritis. *Helicobacter* 2010; 15:510-5.

IF:3.1, Rank: 10/25 (Gastro). Research Student. Contribution: A,B,C,D

35. Kamaysi I, Nseir W, Alexandrov O, Isakson A, Mysh V, Dabbah K, and **Assy N**. Subclinical hepatic encephalopathy in cirrhotic Patients is not aggravated by sedation with propofol compared to midazolam. *J Hepatol*. 2011; 54:72-7.

IF:9.33, Rank: 4/71 (Gastro&hepatol). A.O. Research Student. Contribution: A,B,C,D

36. Nseir W, Hussein T, Khateeb J, Grosovski M, and **Assy N**. Fatty Liver Disease is Associated with Recurrent Bacterial Infections Independently of Metabolic Syndrome. *Dig Dis Sci*. 2011; 56:3328-3334

IF:2.06, Rank: 40/71 (Gastro&hepatol). Contribution: A,B,C,D

Since last promotion

1. Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, **Assy N**. [Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients.](https://www.ncbi.nlm.nih.gov/pubmed/22215943) *World J Gastroenterol*. 2011; 17:5184-90.

IF 3.411 Rank: 35/84 (Gastroenterology & Hepatology). Contribution: A,B,C,D

2. **Nimer A**, Mouch A. [Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients.](https://www.ncbi.nlm.nih.gov/pubmed/22371640) *World J Gastroenterol***.** 2012; 18:800-5.

IF 3.411 Rank: 35/84 (Gastroenterology & Hepatology). Contribution: A,B,C,D

3. Nseir W, Mograbi J, Abu-Elheja O, Bishara J, **Assy N**. [The impact of prior long-term versus short-term statin use on the mortality of bacteraemic patients.](https://www.ncbi.nlm.nih.gov/pubmed/21894571) *Infection*. 2012;40(1):41-8.

IF 2.927 Rank: 39/89 (Infectious Diseases). Contribution: A,B,C,D

4. Nseir W, Mograbi J, Di Castro N, Abu-Elheja O, Abu-Rahmeh Z, Khamaysi I, Samara M, **Assy N**. [On the association between soft drink consumption and Helicobacter pylori infection.](https://www.ncbi.nlm.nih.gov/pubmed/22057241) *Dig Dis Sci*. 2012 ;57:981-6.

IF 2.937 Rank: 48/84 (Gastroenterology & Hepatology). Contribution: A,B,C,D

5. **Assy N**, Basher W, Chetver L, Shnaider J, Zidan J. [First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: a phase II study.](https://www.ncbi.nlm.nih.gov/pubmed/22392022) *J Clin Gastroenterol*. 2012; 46:e27-30.

IF 2.724 Rank: 54/84 (Gastroenterology & Hepatology). Contribution: C,D

6. Elias W, **Assy N**, Elias I, Toledo T, Yassin M, Bowirrat A. [The detrimental danger of Water-Pipe (Hookah) transcends the hazardous consequences of general health to the driving behavior.](https://www.ncbi.nlm.nih.gov/pubmed/22709610) *J Transl Med*. 2012;10:126.

IF 4.098 Rank: 41/136 (Medicine, Research & Experimental). Contribution: A,B,C,D

7. Zelber-Sagi S, Webb M, **Assy N**, Blendis L, Yeshua H, Leshno M, Ratziu V, Halpern Z, Oren R, Santo E. [Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.](https://www.ncbi.nlm.nih.gov/pubmed/23326163) *World J Gastroenterol*. 2013; 19:57-64.

IF 3.411 Rank: 35/84 (Gastroenterology & Hepatology). Contribution: A,B,C,D

8. Josef P, Ali I, Ariel P, Alon M, **Nimer A**. [Relationship between retinal vascular caliber and coronary artery disease in patients with non-alcoholic fatty liver disease (NAFLD).](https://www.ncbi.nlm.nih.gov/pubmed/23924883) *Int J Environ Res Public Health*. 2013; 10:3409-23.

IF 2.14, Rank 73/180 ('Public, Environmental & Occupational Health'). Contribution: A,B,C,D

9. Safadi R, Konikoff FM, Mahamid M, Zelber-Sagi S, Halpern M, Gilat T, Oren R; FLORA Group. [The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease.](https://www.ncbi.nlm.nih.gov/pubmed/24815326) *Clin Gastroenterol Hepatol*. 2014; 12:2085-91.e1.

IF 7.958 Rank: 8/84 (Gastroenterology & Hepatology). Contribution: A,B,C,D

10. Dabbah S, Komarov H, Marmor A, **Assy N**. [Epicardial fat, rather than pericardial fat, is independently associated with diastolic filling in subjects without apparent heart disease.](https://www.ncbi.nlm.nih.gov/pubmed/24675004) *Nutr Metab Cardiovasc Dis*. 2014;24:877-82

IF 3.340 Rank: 33/86 (Nutrition & Dietetics). Contribution: A,B,C,D

11. Lalazar G, Mizrahi M, Turgeman I, Adar T, Ben Ya'acov A, Shabat Y, **Nimer A**, Hemed N, Zolotarovya L, Lichtenstein Y, Lisovoder N, Samira S, Shalit I, Ellis R, Ilan Y. [Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial.](https://www.ncbi.nlm.nih.gov/pubmed/25876706) *J Clin Immunol*. 2015; 35:399-407.

IF 4.128 Rank: 54/158 (Immunology). Contribution: B, D

12. Frank Wolf M, Peleg D, Kariv Silberstein N, **Assy N**, Djibre A, Ben-Shachar I. [Correlation between changes in liver stiffness and preeclampsia as shown by transient elastography.](https://www.ncbi.nlm.nih.gov/pubmed/27391875) *Hypertens Pregnancy*. 2016; 35:536-541.

IF 1.736 Rank: 53/83 (Obstetrics & Gynecology). Contribution: A,B,C,D

13. Flisiak R, Kawazoe S, Znoyko O, **Assy N**, Gadano A, Kao JH, Lee KS, Zwirtes R, Portsmouth S, Dong Y, Xu D, Kumada H, Srinivasan S. [Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b.](https://www.ncbi.nlm.nih.gov/pubmed/27327078) *J Interferon Cytokine Res*. 2016 ;36:635-643.

IF 1.774 Rank: 134/158 (Immunology). Contribution: B,D

14. Farah R, Gilbey P, Grozovski M, Asli H, Khamisy-Farah R, **Assy N**. [Antioxidant Enzyme Activity and Cognition in Obese Individuals with or without Metabolic Risk Factors.](https://www.ncbi.nlm.nih.gov/pubmed/27657994) *Exp Clin Endocrinol Diabetes*. 2016; 124:568-571

IF 1.927 Rank: 115/145 (Endocrinology & Metabolism). Contribution: A,B,C,D

15. Zelber-Sagi S, Bord S, Dror-Lavi G, Smith ML, Towne SD Jr, Buch A, Webb M, Yeshua H, **Nimer A**, Shibolet O. [Role of illness perception and self-efficacy in lifestyle modification among non-alcoholic fatty liver disease patients.](https://www.ncbi.nlm.nih.gov/pubmed/28348495) *World J Gastroenterol*. 2017; 23:1881-1890.

IF 3.411 Rank: 35/84 (Gastroenterology & Hepatology). Contribution: A,B,C,D

16. Gozlan Y, Ben-Ari Z, Moscona R, Shirazi R, Rakovsky A, Kabat A, Veizman E, Berdichevski T, Weiss P, Cohen-Ezra O, Lurie Y, Gafanovich I, Braun M, Cohen-Naftaly M, Shlomai A, Shibolet O, Zigmond E, Zuckerman E, Carmiel-Haggai M, **Nimer A**, Hazzan R, Maor Y, Kitay-Cohen Y, Shemer-Avni Y, Kra-Oz Z, Schreiber L, Peleg O, Sierra S, Harrigan PR, Mendelson E, Mor O. [HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patients.](https://www.ncbi.nlm.nih.gov/pubmed/28067632) *Antivir Ther*. 2017; 22:431-441.

IF 2.305 Rank: 23/36 (Virology). Contribution: B,D

17. Eliyahu S, Sharabi O, Elmedvi S, Timor R, Davidovich A, Vigneault F, Clouser C, Hope R, **Nimer A**, Braun M, Weiss YY, Polak P, Yaari G, Gal-Tanamy M. [Antibody Repertoire Analysis of Hepatitis C Virus Infections Identifies Immune Signatures Associated With Spontaneous Clearance.](https://www.ncbi.nlm.nih.gov/pubmed/30622532) *Front Immunol*. 2018;9:3004.

IF 4.716 Rank: 43/158 (Immunology). Contribution: B,D

18. Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Pitt B; FIGARO-DKD study investigators. [Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.](https://www.ncbi.nlm.nih.gov/pubmed/31665733) *Am J Nephrol*. 2019; 50:345-356

IF 2.961 Rank: 20/80 (Urology & Nephrology). Contribution: B,D

19. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G; on behalf of the FIDELIO-DKD study investigators; FIDELIO-DKD study investigators. [Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.](https://www.ncbi.nlm.nih.gov/pubmed/31655812) *Am J Nephrol*. 2019;50:333-344

IF 2.961 Rank: 20/80 (Urology & Nephrology). Contribution: B,D

20. Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group. [*Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.*](https://www.ncbi.nlm.nih.gov/pubmed/31553834) *N Engl J Med.*2019;381:1215-1226.

IF 70.670 Rank: 1/160 (Medicine, General & Internal). Contribution: B,D

21. Perez S, Kaspi A, Domovitz T, Davidovich A, Lavi-Itzkovitz A, Meirson T, Alison Holmes J, Dai CY, Huang CF, Chung RT, **Nimer A**, El-Osta A, Yaari G, Stemmer SM, Yu ML, Haviv I, Gal-Tanamy M. [Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals.](https://www.ncbi.nlm.nih.gov/pubmed/31216276) *PLoS Genet*. 2019; 15:e1008181.

IF 5.224 Rank: 23/173 (Genetics & Heredity). Contribution: B,D

22. Gozlan Y, Bucris E, Shirazi R, Rakovsky A, Ben-Ari Z, Davidov Y, Veizman E, Saadi T, Braun M, Cohen-Naftaly M, Shlomai A, Shibolet O, Zigmond E, Katchman H, Menachem Y, Safadi R, Galun E, Zuckerman E, **Nimer A**, Hazzan R, Maor Y, Saif AM, Etzion O, Lurie Y, Mendelson E, Mor O. [High frequency of multiclass HCV resistance-associated mutations in patients failing direct-acting antivirals: real-life data.](https://www.ncbi.nlm.nih.gov/pubmed/30880684) *Antivir Ther*. 2019; 24:221-228.

IF 2.305 Rank: 23/36 (Virology). Contribution: B,D

23. Lim JJ, Nilsson AC, Silverman M, **Assy N**, Kulkarni P, McBride JM, Deng R, Li C, Yang X, Nguyen A, Horn P, Maia M, Castro A, Peck MC, Galanter J, Chu T, Newton EM, Tavel JA. [A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection.](https://pubmed.ncbi.nlm.nih.gov/32393496/) *Antimicrob Agents Chemother*. 2020; 64:e00352-20.

24. Kadah A, Khoury T, Mahamid M, **Assy N**, Sbeit W. [Predicting common bile duct stones by non-invasive parameters.](https://www.ncbi.nlm.nih.gov/pubmed/31810810) *Hepatobiliary Pancreat Dis Int*. 2020;19(3),266-270.

IF 1.576 Rank: 78/84 (Gastroenterology & Hepatology). Contribution: C, D

25. **Assy N,** Saad E, Basheer M, Assy Najib and Sbeit W*.* New Predictor of Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis. *Clin Gastroenterol Int*. 2021; 3(1):1017.

26. Basheer M, Saad E and **Assy N.** Low (HDL) Lipoprotein Levels is Strongly Correlated with The Severity of Covid-19 Pneumonia. *Japanese J Gastro Hepato*. 2021;V5(12):1-2

27. Basheer M, Saad E and **Assy N.** Methylprednisolone Decrease In-Hospital Mortality in Patients with COVID-19 Pneumonia. *Japanese J Gastro Hepato*. 2021;V5(12):1-1

1. **Clinical Descriptive Research**

Until last promotion

1. **Assy N**, Blumenfeld Z, Berkovitz D, Nave Y, Kramsky R, Rosenthal E, Enat R, and

 Baruch Y. Long term follow up of liver transplant patients in a non-liver transplantation center. *Transplant Proceed* 1997; 29:2664-2666.

IF: 0.99, Rank: x/y (Transplant). Contribution: A,B,C,D

2. Edoute Y, Malberger E, Tibon-Fisher O, **Assy N**. Non- imaging-guided fine needle aspiration of liver lesions: A retrospective study of 279 patients. *World J Gastroenterology (WJG)* 1999; 5:98-103. **Invited Commentary**.

IF: 2.24, Rank: 35/71(Gastro&hepatol). Contribution: A,B,C,D

3. Hoffman R, Assy N, Lanir N, Brenner B, Baruch Y. Budd-Chiari syndrome associated with factor V Leiden mutation: A report of 6 patients. *Liver Transpl Surg* 1999; 5:96-100.

IF:3.05, Rank: 10/25 (Transplantation). Contribution: A,B,C,D

4. Assy N, Minuk GY. A comparison between previous and present histologic assessments of chronic hepatitis C viral infection in humans. *World J Gastroenterology* 1999; 5:107-111.

IF: 2.24, Rank: 35/71 (Gastro&hepatol). Contribution: A,B,C,D

Since last promotion

1. Shalata A, Mahroom M, Milewicz DM, Limin G, Kassum F, Badarna K, Tarabeih N, **Assy N**, Fell R, Cohen H, Nashashibi M, Livoff A, Azab M, Habib G, Geiger D, Weissbrod O, Nseir W. [Fatal thoracic aortic aneurysm and dissection in a large family with a novel MYLK gene mutation: delineation of the clinical phenotype.](https://www.ncbi.nlm.nih.gov/pubmed/29544503) *Orphanet J Rare Dis*. 2018;13(1):41.

IF 3.687 Rank: 48/173 (Genetics & Heredity), (D)

2. Meerson A, Najjar A, Saad E, Sbeit W, Barhoum M, **Assy N**. [Sex Differences in Plasma MicroRNA Biomarkers of Early and Complicated Diabetes Mellitus in Israeli Arab and Jewish Patients.](https://www.ncbi.nlm.nih.gov/pubmed/30959814) *Noncoding RNA*. 2019 ;5(2): 32.

IF 2.03, Rank 7784 (Biochemistry ; Genetics ; Molecular Biology**)** (A,B,C,D)

3. Saad E, Sbeit W, Barhoum M, Levy G, **Assy N**. Seasonal Patterns of Acute Esophageal Variceal Bleeding in Patients with Liver Cirrhosis. *Japanese Journal of Gastroenterology and Hepatology* 2020, V3(1):1-6.

IF 1.690, Rank (Gastroenterology & Hepatology), (A,B,C,D)

1. **Case reports**

Until last promotion

1. **Assy N,** Rosenthal E, Hazani A, Etzioni A,Baruch Y. Human parvovirus B19 infection 1

associated with idiopathic thrombocytopenic purpura in a child following liver transplantation. *J Hepatol* 1997:27:934-936.

IF:9.33, Rank: 4/71 (Gastro&hepatol). Contribution: A,B,C,D

2. Edoute Y, Lachter J, Furman E, and **Assy N**. Severe cholestatic jaundice induced by EBV infection in the elderly. *J Gastroenterol Hepatol* 1998; 13:821-824.

IF:2.4, Rank: 33/71(Gastro&hepatol). Contribution: A,B,C,D

3. Miron D, Olshinsky A, **Assy N**, Zuker M, Efrat M, Hussein O. Plasmodium and Borrelia coinfection. *J Travel Med* 2004; 11:115-116.

IF:1.47, Rank: ? (Infection disease). Contribution: D

4. **Assy N**, Khair G, Sorina Schlesinger, and Osamah Hussein.Severe cholestatic jaundice in the elderly induced by low dose amiodarone. *Dig Dis Sci* 2004, 49: 450-2.

IF:2.06, Rank: 40/71(Gastro&hepatol). Contribution: A,B,C,D

5. **Assy N**, Schlesinger S, Miron D, Hussein O. Cycling of antibiotics for the prophylaxis of recurrent spontaneous bacterial peritonitis in a cirrhotic patient. *World J Gastroenterology* 2005; 11:6407-6408.

IF: 2.24, Rank: 35/71(Gastro&hepatol). Contribution: A,B,C,D

6. **Assy N**, Gefen H, Schlesinger S, and Hussein O. The beneficial effect of N-acetylcysteine and ciprofloxacin therapy on the outcome of ischemic fulminant hepatic failure *Dig Dis Sci*. 2007;52(12):3507-10.

IF:2.06, Rank: 40/71(Gastro&hepatol). Contribution: A,B,C,D

7. **Assy N**, Gefen H, Schlesinger S, and Karim W. Reactivation versus primary CMV infection after splenectomy in immunocompetent patient. *Dig Dis Sci* 2007; 52, 3477-3480.

IF:2.06, Rank: 40/71(Gastro&hepatol). Contribution: A,B,C,D

8. Benyashvili Z, Djibre A, **Assy N**. Fulminant Kliebsella pneumoniae pneumonia in immunocompromized patient. *Clinical Medicine* 2008;1: 81-82 (A,B,C,D; **viewed at libertas academia 1298 times)**

IF:1.04, Rank: ? (Gastro&hepatol ). Contribution: A,B,C,D

9. Nassar F, Nasser M and **Assy N,** Epstein-Barr virus-associated fulminant hepatic failure and autoimmune hemolytic anemia. *Gastrohep.com* 19 December 2008.

10. N. Samuel,Y. Ezri, R. Farah, V. Igor, A. Hussein, O. Rubinshtein, **N. Assy**. Acute Aflatoxicosis Resulting in Fulminant Hepatic Failure and Rhabdomyolysis. *Gastroenterology Research* 2009, 2: 48-50.

11. Nassar F, Vaisbein E, and **Assy N**. Autoimmune hepatitis - SLE overlap syndrome. *Gastrohep.com* 30 January 2009.

12. G Murad, R Shaheen, R Farah, and **N Assy**, [Severe acute cholestatic hepatitis with encephalitis induced by Epstein-Barr virus infection](http://www.gastrohep.com/classcases/classcases.asp?id=46). *Gastrohep.com*. 22 April 2009.

13. Djibre A, Zohar S and **Assy N**, [Acute fatty liver of pregnancy](http://www.gastrohep.com/classcases/classcases.asp?id=49). *Gastrohep.com* 30 March 2010

14. Djibre A, Szvalb S and **Assy N**, [D-penicillamine-induced skin elastosis perforans serpiginosa](http://www.gastrohep.com/classcases/classcases.asp?id=50). *Gastrohep.com* 19 April 2010.

Since last promotion

1. A Djibre, **N Assy:**  [Recurrent postpartum autoimmune hepatitis](https://scholar.google.co.il/citations?view_op=view_citation&hl=en&user=JkNboioAAAAJ&sortby=pubdate&citation_for_view=JkNboioAAAAJ:LPZeul_q3PIC) *Gastrohep.com* 11 June 2013.

2. W Sbeit, **N Assy**, A Kadah, M Farraj, M Barhoum, M Musa, M Shiller Foley Catheter Gastric Tube Feeding Migration as a Cause of Acute Pancreatitis. *Journal of Pancreas*. 2017; 18, 170-174

1. **Review Papers**

Until last promotion

1. Minuk GY and **Assy N.** The consequences of hepatitis C viral infections. *Can J Gastroenterology* 1995; 9:373-376.

IF: 1.55, Rank: 49/71 (Gastro&hepatol ). Contribution: A,B,C,D

2. **Assy N**, and Minuk GY. Liver regeneration: methods for monitoring and their applications. *J Hepatol* 1997:26:945-952.

IF: 9.33, Rank: 3/71 (Gastro&hepatol). BY. Research Student. Contribution: A,B,C,D

3. **Assy N**, and Minuk GY. Liver Disease in pregnancy. *J Am Coll Surg* 1997; 183:643-653.

IF: 4.2, Rank: 7/40 (Surgery). Contribution: A,B,C,D

4. **Assy N**, Jacob G, Spira G, and Edout Y: Diagnostic approach to patients with cholestatic jaundice. *World J Gastroenterology (WJG)* 1999; 5:252-262. (**Invited review**).

IF: 2.24, Rank: 35/71(Gastro&hepatol). Contribution: A,B,C,D

5. Cohen AJ, **Assy N**, Moser M, and Minuk GY. Viral hepatitis and the surgeon. *HPB* 2005; 7:56-64.

IF:1.285, Rank: 54/71 (Gastro&hepatol. Contribution: A,B,C,D

6. **Assy** N, Assy NN, Samuel N, Lerman A, Nseir W. Approach to solid liver masses in the cirrhotic patient. *Gastroenterology research*. 2009(2): 259-267.

IF: 0.5, Rank: ? (Gastro&hepatol ). Contribution: A,B,C,D

7. **Assy N**, Nassar F, Nasser G, Grosovski M. [Olive oil consumption and non-alcoholic fatty liver disease.](http://www.ncbi.nlm.nih.gov/pubmed/19370776) *World J Gastroenterol*. 2009 ;15:1809-15.

IF: 2.24, Rank: 35/71 (Gastro&hepatol). Contribution: A,B,C,D

8. **Assy N**, Nasser G, Djibre A, Beniashvili Z, Elias S, Zidan J. [Characteristics of common solid liver lesions and recommendations for diagnostic workup.](http://www.ncbi.nlm.nih.gov/pubmed/19598296) *World J Gastroenterol*. 2009; 15:3217-27

IF: 2.24, Rank: 35/71 (Gastro&hepatol). Contribution: A,B,C,D

9. W. Nseir, F. Nassar, **N. Assy.** Soft drinks consumption and nonalcoholic fatty liver disease. *World journal Gastroenterol*, 2009 Jul 14;15 :3217-27.

IF: 2.24, Rank: 35/71 (Gastro&hepatol). Contribution: A,B,C,D

10. Nseir W, Shalata A, Marmor A, and **Assy N.** Mechanisms Linking Non-Alcoholic Fatty Liver Disease with Coronary Artery Disease. *Dig Dis SCI* 2011;56:3439-49.

IF:2.06, Rank: 40/71 (Gastro&hepatol). Contribution: A,B,C,D

11. **Assy N.** [Nutritional recommendations for patients with non-alcoholic fatty liver diseases.](http://www.ncbi.nlm.nih.gov/pubmed/21876629) *World J Gastroenterol*. 2011; 17:3375-6

Since last promotion

1. Nseir W, Hellou E, **Assy N**. [Role of diet and lifestyle changes in nonalcoholic fatty liver disease.](https://www.ncbi.nlm.nih.gov/pubmed/25071328) *World J Gastroenterol*. 2014; 20:9338-44.

IF 3.411 Rank: 35/84 (Gastroenterology & Hepatology), (A,B,C,D)

2. Elias S, Wisam S, Luai A, Massad B, **Nimer A**. [Lipotoxicity in Obesity: Benefit of Olive Oil.](https://www.ncbi.nlm.nih.gov/pubmed/28585218) *Adv Exp Med Biol*. 2017;960:607-617.

IF 2.126 Rank: 86/136 (Medicine, Research & Experimental), (A,B,C,D)

1. **Other Publications**

Until last promotion

1. Edoute Y, Malberger E, Tibon-Fisher O, **Assy N**. Non-imaging-guided fine needle aspiration of liver lesions: Invited Commentary *WJG* 1999; 5:98-102.

IF: 2.24, Rank: 35/71 (Gastro&hepatol). Contribution: A,B,C,D

2. **Assy N**, Schlesinger S, Hussein O. Acute hepatitis with extremely high ferritin levels and Still's disease. *J Hepatol*. 2001; 35:830-831.

IF: 9.33, Rank: 3/71 (Gastro&hepatol). Contribution: A,B,C,D

3. **Assy N**, Hussein. Peg interferon and lamivudine for hepatitis B O. *New Engl J Med*. 2004; 30; 351(27):2879.

IF: 53.4, Rank: 1/151 (medicine, general & internal). Contribution: A,B,C,D

4. **Assy N**, Schlesinger S, and Hussein O. Elevated plasma protein C correlates with the presence of fatty liver (NASH and NAFLD). *Gut* 2005;54(5):729.

IF: 10.6, Rank: 3/71 (Gastro&hepatol). Contribution: A,B,C,D

5. **Assy N**, Schlesinger S, Miron D, Hussein O. Cycling of antibiotics for the prophylaxis of recurrent spontaneous bacterial peritonitis in a cirrhotic patient. *World J Gastroenterology* 2005; 11:6402-6402.

IF: 2.24, Rank: 35/71 (Gastro&hepatol). Contribution: A,B,C,D

6. **Assy N**, Schlesinger S, Hussein O. Beta-blockers to prevent gastro esophageal varices in cirrhosis. *N Engl J Med* 2006; 23; 353:1318.

IF: 53.4, Rank: 1/151 (medicine, general & internal). Contribution: A,B,C,D

7. [**Assy N**, Embon O.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17380576&query_hl=12&itool=pubmed_docsum) Peginterferon and ribavirin for hepatitis C. *N Engl J Med* 2007: 22;356:1269.

IF: 53.4, Rank: 1/151 (medicine, general & internal). Contribution: A,B,C,D

8. **Assy N**, Beniashvili Z, Nseir W, and Embon Oscaar. Day-case liver biopsy: a prospective study of 300 cases. *Am J Gastroenterology*: 2007; 102:2611-2.

IF: 6.88, Rank: 5/71 (Gastro&hepatol). Contribution: A,B,C,D

 9. **Assy N**, Adams P, and Ghent CN. A randomized controlled trial of total immunosuppression withdrawal in stable liver transplant recipients. *Gut* 2007: 56:304-312.

IF: 10.6, Rank: 3/71 (Gastro&hepatol). Contribution: A,B,C,D

10. **Assy N**, Nseir W. Letter to the Editor: Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. *J Hepatol* 2010; 52:951-954.

IF: 9.33, Rank: 3/71 (Gastro&hepatol). Contribution: A,B,C,D

11. **Assy N**, Khamayse I. [Sub clinical hepatic encephalopathy in cirrhotic patients is not aggravated by sedation with propofol compared to midazolam: A randomized controlled study.](http://www.ncbi.nlm.nih.gov/pubmed/21145929) *J Hepatol*. 2011 54(1), 72-77.

IF: 9.33, Rank: 3/71(Gastro&hepatol). Contribution: A,B,C,D

12. S. Zelberg-Sagi, V. Ratziu, R. Oren. Nutritional and physical activity in NAFLD: An overview of the epidemiological evidence. *WJG* 2011, 17(29): 3377-3389. **Series Editor**

IF: 2.24, Rank: 35/71(Gastro&hepatol). Contribution: A,B,C,D

13. **Assy N.** Nutritional recommendation of patients with Nonalcoholic fatty liver diseases (NAFLD). *World J Gastroenterol* 2011; 17(29):3375-6: Invited editorial to WJG 2010 as an expert in the field (Highlights 2011).

IF: 2.24, Rank: 35/71(Gastro&hepatol). Contribution: A,B,C,D,

Since last promotion

Letters to the Editor

1. Sbeit W, **Assy N**, Farraj M, Kadah A, Shiller M. [Comment on ACG and CAG Clinical Guidelines for Management of Dyspesia.](https://www.ncbi.nlm.nih.gov/pubmed/29610506) Am J Gastroenterol. 2018; 113:623-624.

IF 10.241 Rank: 7/84 (Gastroenterology & Hepatology), (C,D)

2. **Assy N**, Barhoum M. [Sofosbuvir and Velpatasvir for Patients with HCV Infection [Letter].](https://www.ncbi.nlm.nih.gov/pubmed/27119243) N Engl J Med. 2016;374:1687

IF 70.670 Rank: 1/160 (Medicine, General & Internal) (A,B,C,D)

1. **Book chapters**

Until last promotion

1. **Nimer Assy**, Faris Nassar and Maria Grosovski, Monounsaturated Fat Enriched with Olive Oil in Non-alcoholic Fatty Liver Disease. In: Victor R. Preedy and Ronald Ross Watson, editors, *Olives and Olive Oil in Health and Disease Prevention*. Oxford:Academic Press, 2010, pp. 1151-1156.

2. Nseir W, and **Assy Nimer**. Mechanisms Linking Non-Alcoholic Fatty Liver Disease with Coronary Artery Disease. *Coronary Angiography / Book 3*. Full Chapter Submission: 31 March, 2011. InTech - Open Access Publisher.

Since last promotion

1. **N Assy,** F Adawi. W Nseir. Role of Fructose in Body Functions: An Overview. In: BM. Johnston and A.B Collins (Eds), *Fructose synthesis function and health implications*. Nova science publishers, 2012, 101-106.

2. Elias S., Masad B., **Nimer A.** Serum Biomarkers for Evaluating Portal Hypertension. In: Patel V., Preedy V. (eds) *Biomarkers in Liver Disease. Biomarkers in Disease: Methods, Discoveries and Applications*. Springer: Dordrecht, 2017, 153-167.

3. Elias S., Wisam S., Luai A., Massad B., **Nimer A**. Lipotoxicity in Obesity: Benefit of Olive Oil. In: Engin A., Engin A. (eds) *Obesity and Lipotoxicity. Advances in Experimental Medicine and Biology*. Springer: Cham, 2017; 960: 607-617

4. Azulay EE, **Assy N**, Cohen, Interleukin-1.In:eLS Immunology. John Wiley & Sons, Ltd: Chischester. 2018,Pp.

1. **Publications with No\_IF**

Until last promotion

1. **Assy N**. Consequence of Chronic HCV infection. *Maccabi Health Service Letters*. 1997

2. Kayal M, Dabus S, **Assy N**. Changes in Kidney Function (GFR) after Furosemide administration in Patients with compensated cirrhosis. *The Medical* 2009.

3. N. Samuel, Y. Ezri, R. Farah, Vacksman I., A. Hussein, O. Rubinstein, **N. Assy.** Acute aflatoxicosis resulting in fulminant hepatic failure and rhabdomyolysis. *Gastroenterology Research* 2(1), Feb 2009.

4. **Assy N**: Pharmacological treatment in NAFLD. Led by Oren R; *Medical Media, fatty liver* 2009.

5. **Nimer Assy**, Najib assy, Nir samuel, Arcadi Lerman, Nseir william. Approach to solid liver mass in the cirrhotic patient. *Gastroenterology Research*; 2(5), Oct 2009.

6. Dabush S, Djibree A, Nseir W, **Assy N**. Pharmacologic treatment of fatty liver. *The Medical* 2010.

7. **Assy N**, Abu Mouch S. Vitamin D could help fight hepatitis C. Vitamin D may also be key to curing hepatitis. But Israelis, especially the ultra-Orthodox, are woefully deficient. *Haaretz Daily*, 14.01.2010.

1. **רשימת פטנטים**:
* July 2009, Grosovski M, Maoz M, **Assy N**. Therapy of NAFLD utilizing Inula Viscosa Extract. State of Israel. **Application** **Number 199847**
* December 2009 Grosovski M, Maoz M, **Assy N**. A cola beverage containing inula viscose extract for consumers suffering from NAFLD, State of Israel. **Application Number 202218**
1. **פרופיל אקדמי**:

**Main Research Interests and Achievements**

* יחידת מחקרים קליניים במחלקה פנימית א': השתתפות בכ-60 מחקרים קליניים כחוקר ראשי בשמונה השנים האחרונות, במגוון רב של תחומי רפואה פנימית. בשנת 2022 רשומים 23 מחקרים קליניים בהם מופיע כחוקר ראשי.
* הקמת מעבדת מחקר לחקר הכבד במרכז הרפואי לגליל.

**Most Significant Past Achievements**

* Citations: 5783 times; h-index 33; i10-index 58
* More than 20 papers in top 5 hepatology journals, including Journal of Hepatology (10 papers), Gut (3 papers), Hepatology (2 papers), American Journal of Gastroenterology (5 papers), and New England Journal of Medicine (5 letters).
* Most important studies with high clinical implication:

1) Soft drinks are linked with fatty liver disease (J Hepatol 2009)

2) Association between cardiovascular disease and fatty liver disease (radiology 2010)

3) Vitamin D supplement to peg/rib treatment for patients with HCV viral infection (AASLD LB, EASL ORAL, WJG 2011 in press)

4) IGF-1 generation reflects synthetic liver dysfunction in patients with cirrhosis (J Hepatol 1997)

5) Sedation with propofil in patients with cirrhosis (J Hepatol 2010, Gastrointestinal Endoscopy 1999)

6) VEGF role in liver regeneration (J Hepatol 1999)

7) New molecular (PCNA) marker to document extent of liver regeneration (J Lab Clin Med 1998)

**Future Goals**

* Continue promoting my research lab in GMC for MSc and PhD students’ theses
* Continue clinical medical research with pharmaceutical companies
* Continue teaching in the faculty of medicine: clerkship, bioenergetics, liver disease, liver transplantation
* Continue being the most prolific and productive department of internal medicine at Bar Ilan University
* תוכנית מצפן, שרות המטולוגי ומרפאת כבד פנימית
1. **חיוניות לפקולטה**:

תאריך: חתימת הדיקן:\_\_\_\_\_\_\_\_\_\_